# EDGAR Filing Document

**Accession Number:** 0001626971
**File Stem:** 0000000000-23-003261
**Filing Date:** 2023-3
**Character Count:** 3280
**Document Hash:** ca203ca7631b502bec4c210eb5cc08c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003261.hdr.sgml**: 20230606

**ACCESSION NUMBER**: 0000000000-23-003261

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230331

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corvus Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001626971
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464670809
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 863 MITTEN ROAD
- **STREET 2:** SUITE 102
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010
- **BUSINESS PHONE:** (650) 900-4520

**MAIL ADDRESS:**
- **STREET 1:** 863 MITTEN ROAD
- **STREET 2:** SUITE 102
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-082535

## Text-Extract

```

United States securities and exchange commission logo

                        March 31, 2023

       Leiv Lei
       Chief Financial Officer
       Corvus Pharmaceuticals, Inc.
       63 Mitten Road, Suite 102
       Burlingame, CA 94010

                                                        Re: Corvus
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 29,
2023
                                                            File No. 333-270921

       Dear Leiv Lei :

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jimmy
McNamara at 202-551-7349 with any questions.

                        Sincerely,

                        Division of Corporation Finance

                        Office of Life Sciences
       cc:                                              Phillip Stoup

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 31, 2023

Leiv Lei
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
63 Mitten Road, Suite 102
Burlingame, CA 94010

Re: Corvus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 29, 2023
File No. 333-270921

Dear Leiv Lei :

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Phillip Stoup